15964 Randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti–interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis

Abstract

Background: This randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study (NCT02980692) evaluated the efficacy and safety of tildrakizumab (TIL)—a high-affinity anti–interleukin-23p19 monoclonal antibody—in patients with active psoriatic arthritis (PsA) to week 24.